



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/719,311	11/20/2003	John A. Chiorini	14014.0252U3	3284
36339	7590	06/28/2006	EXAMINER	
NATIONAL INSTITUTE OF HEALTH C/O NEEDLE & ROSENBERG, P.C. SUITE 1000 999 PEACHTREE STREET ATLANTA, GA 30303			KAUSHAL, SUMESH	
			ART UNIT	PAPER NUMBER
			1633	
DATE MAILED: 06/28/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/719,311	CHIORINI ET AL.
	Examiner Sumesh Kaushal Ph.D.	Art Unit 1633

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE ____ MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 04 June 2004.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-42 is/are pending in the application.
4a) Of the above claim(s) _____ is/are withdrawn from consideration.
5) Claim(s) _____ is/are allowed.
6) Claim(s) 1-42 is/are rejected.
7) Claim(s) _____ is/are objected to.
8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 6/4/04.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ .
5) Notice of Informal Patent Application (PTO-152)
6) Other: ____ .

DETAILED ACTION

Applicant's response filed on 06/04/04 has been acknowledged.

Claims 1-42 are pending and are examined in this office action.

Applicants are required to follow Amendment Practice under revised 37 CFR §1.121. The fax phone numbers for the organization where this application or proceeding is assigned is 571-273-8300.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-42 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The scope of invention as claimed encompasses a recombinant genetic material (vector system) having characteristic of AAV4 comprising a nucleic acid encoding AAV4 capsid protein. The scope of invention as claimed further encompasses variant of AAV4 Rep proteins (SEQ ID NO(s): 2, 8, 9, 10 and 11) and AAV4 Capsid proteins (SEQ ID NO(s): 4, 16 and 18) which are only 95-98% identical to the disclosed representative ptoeirns. Besides the nucleotide sequence of SEQ ID NO:1 which encodes AAV4 genome, AAV4 Rep proteins (SEQ ID NO(s): 2, 8, 9, 10 and 11) and AAV4 Capsid proteins (SEQ ID NO(s): 4, 16 and 18) the specification as failed fails to disclose any variants of AAV4 Rep and capsid proteins. In addition besides the nucleotide sequence of SEQ ID NO:1 which encodes AAV4 genome, the speciation as field fails to disclose

any other vector for producing infectious virus particles having characteristic of AAV4 that contains any and all characteristic of AAV4.

Applicant is referred to the guidelines for ***Written Description Requirement*** published January 5, 2001 in the Federal Register, Vol.66, No.4, pp.1099-1110 (see <http://www.uspto.gov>). The disclosure of a single species is rarely, if ever, sufficient to describe a broad genus, particularly when the specification fails to describe the features of that genus, even in passing. (see *In re Shokal* 113USPQ283(CCPA1957); *Purdue Pharma L. P. vs Faulding Inc.* 56 USPQ2nd 1481 (CAFC 2000). In analyzing whether the written description requirement is met for the genus claim, it is first determined whether a representative number of species have been described by their complete structure. Next, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics (i.e conserve motifs or domains).

The specification fails to disclose representative number of species by structure and function encompassed by genus as claimed. Furthermore the genus as claimed encompasses structurally and functionally distinct members. Claiming all divergent species that achieve a result as contemplated by the application without defining the representative number of species by structure and function is not in compliance with the written description requirement. Rather, it is an attempt to preempt the future before it has arrived. "The written description requirement has several policy objectives. The essential goal' of the description of the invention requirement is to clearly convey the information that an applicant has invented the subject matter which is claimed." *In re Barker*, 559 F.2d 588, 592 n.4, 194 USPQ 470, 473 n.4 (CCPA 1977).

The art at the time of filing teaches that AAV4 has considerable homology with AAV2 and AAV3 (Chiorini et al J. Virol, 71(9):6823-33, 1997, see abstract, figure-1, figure-3, ref of record on PTO-1449). Therefore it is unclear how one skill in the art could possibly know what are the characteristic of AAV4 unless one skill in the art knows all known AAV-sequences and AAV sequences yet to be discovered in this context. In this case applicant only disclosed AAV4 (SEQ ID NO:1) and proposes to discover other members of the genus using a hybridization procedure. Another

objective is to put the public in possession of what the applicant claims as the invention. See Regents of the University of California v. Eli Lilly, 119 F.3d 1559, 1566, 43USPQ2d 1398, 1404 (Fed. Cir. 1997), cert. denied, 523 U.S. 1089 (1998)." To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail such that the Artisan can reasonably conclude that the inventor(s) had possession of the claimed invention. Such possession may be demonstrated by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and/or formulae that fully set forth the claimed invention. Possession may be shown by an actual reduction to practice, showing that the invention as claimed is "ready for patenting", or by describing distinguishing identifying characteristics sufficient to show that applicant was in possession of the claimed invention (January 5, 2001 Fed.Reg., Vo.66, No. 4, pp. 1099-11).

Since the specification fails to disclose a representative number of species defined by structure and function, it is not possible to envision the claimed composition. One cannot describe what one has not conceived. (See Fiddes v. Baird, 30 USP2d 1481 at 1483). Therefore, the lack of disclosure in the specification is not deemed sufficient to reasonably convey to one skilled in the art that the applicants were in possession of the huge genera recited in the claims at the time the application was filed. Furthermore the possession may be shown by actual reduction to practice, clear depiction of the invention in a detailed drawing, or by describing the invention with sufficient relevant identifying characteristics (as it relates to the claimed invention as a whole) such that a person skilled in the art would recognize that the inventor had possession of the claimed invention. See, e.g., *Pfaff v. Wells Electronics, Inc.*, 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641, 1647 (1998); *Eli Lilly*, 119 F.3d at 1568, 43 USPQ2d at 1406; *Amgen, Inc. v. Chugai Pharmaceutical*, 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991).

In claims to genetic material, generic statement such as "vertebrate insulin cDNA" or mammalian insulin cDNA," without more, is not adequate written description of claimed genus, since it does not distinguish genus from others except by function, and does not specifically define any of genes that fall within its definition, or describe

structural features commonly possessed by members of genus that distinguish them from others; accordingly, naming type of material generally known to exist, in absence of knowledge as to what that material consists of, is not description of that material (*Eli Lilly*, 119 F.3d at 1568, 43 USPQ2d at 1406). In the instant case the recombinant vector system as claimed has been defined only by a statement of function that broadly encompasses having any and all characteristic of AAV4, which conveyed no distinguishing information about the identity of the claimed genetic material, such as its relevant structural or physical characteristics. According to these facts, one skill in the art would conclude that applicant was not in the possession of the claimed genus because a description of even a single member of this genus would not be representative of other nucleic acid constructs genus and is insufficient to support the claim.

Claims 1-42 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Since the specification fails to disclose a representative number of species defined by structure and function (any nucleotide that have any and all characteristic of AAV4, variants of AAV4 rep and capsid proteins), it is unclear how one skilled in the art use the invention as claimed (supra). The applicant's disclosure does not enable one skilled in the art to practice the invention as claimed without further undue amount of experimentation, which requires the identification and characterization of any and all nucleic acid sequences any and all vectors systems or required to produce a vector system having any and all characteristic of AAV4. As stated above the art at the time of filing teaches that AAV4 has considerable homology with AAV2 and AAV3 (Chiorini et al J. Virol, 71(9):6823-33, 1997, see abstract, figure-1, figure-3, ref of record on PTO-1449). The disclosure "shall inform how to use, not how to find out how to use for themselves." See *In re Gardner* 475 F.2d 1389, 177 USPQ 396 (CCPA 1973).

Therefore it is unclear how one skill in the art could possibly know what are the characteristic of AAV4 unless one skill in the art knows all known AAV-sequences and AAV sequences yet to be discovered in this context. In this case applicant only disclosed AAV4 genome (SEQ ID NO:1), AAV4 Rep proteins (SEQ ID NO(s): 2, 8, 9, 10 and 11) and AAV4 Capsid proteins (SEQ ID NO(s): 4, 16 and 18); and proposes to discover other members of the genus using a hybridization procedure. At issue, under the enablement requirement of 35 U.S.C. 1 12, first paragraph is whether, given the Wands-factors, the experimentation was undue or unreasonable under the circumstances. "Experimentation must not require ingenuity beyond that to be expected of one of ordinary skill in the art." See *Fields v. Conover*, 443 F.2d 1386, 170 USPQ 276 (CCPA 1970).

Furthermore, USPTO does not have laboratory facilities to test if an invention will function as claimed when working examples are not disclosed in the specification, therefore, enablement issues are raised and discussed based on the state of knowledge pertinent to an art at the time of the invention, therefore skepticism raised in the enablement rejections are those raised in the art by artisans of skill.

In addition, it is noted that patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable (See *Brenner v. Manson*, 383 U.S. 519, 536, 148 USPQ 689, 696 (1966), *Stating, in context of the utility requirement, that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion."*) Tossing out the mere germ of an idea does not constitute enabling disclosure. While every aspect of a generic claim certainly need not have been carried out by an inventor, or exemplified in the specification, reasonable detail must be provided in order to enable members of the public to understand and carry out the invention.

It is noted that the unpredictability of a particular area may alone provide reasonable doubt as to the accuracy of the broad statement made in support of enablement of claims. See *Ex parte Singh*, 17 USPQ2d 1714 (BPAI 1991). Therefore considering the state of the art and limited amount of guidance provided in the instant

specification, one skill in the art would have to engage in excessive and undue amount of experimentation to exercise the invention as claimed.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 9 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims are generally narrative and indefinite, failing to conform with current U.S. practice. They appear to be a literal translation into English from a foreign document and are replete with grammatical and idiomatic errors. The instant claim recites claim limitation "theAAV4" in line 1. Changing "theAAV4" to – the AAV4 – has been suggested.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Muser et al (Virlogy 35(3):653-61, 1980).

Given the broadest reasonable interpretation the scope of invention as claimed encompasses a nucleic acid encoding an AAV4 capsid protein

Muster teaches isolation of AAV4 DNA and physical mapping of the AAV4 genome, which clearly comprises a nucleotide sequence encoding an AAV4 capsid

protein and have the characteristic of AAV4 (page 653, abstract, col.1 para.1). Muster teaches isolation of AAV4 virions from the host cells, followed by isolation of AAV4 DNA from the purified virions (page 654, col.1 para.3-4). Thus the cited art clearly anticipate the invention as claimed because the composition and functions as claimed are presumed inherent in the prior art regarding AAV DNA. The composition is physically the same it must have the same properties. "Products of identical chemical composition can not have mutually exclusive properties." A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. See *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990) see MPEP § 2112.02.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sumesh Kaushal Ph.D. whose telephone number is 571-272-0769. The examiner can normally be reached on Mon-Fri. from 9AM-5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave Nguyen can be reached on 571-272-0731.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to **571-272-0547**. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199. The fax phone number for the organization where this application or proceeding is assigned is **571-273-8300**



SUMESH KAUSHAL
PRIMARY EXAMINER
ART UNIT 1633